Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin W Bergmann

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
ESC Heart Failure|October 13, 2018
Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fractionDavid M Kaye, Mark C Petrie, Scott McKenzie, et al.
Journal of Clinical Medicine|August 23, 2020
Evaluation of Myocardial Gene Expression Profiling for Superior Diagnosis of Idiopathic Giant-Cell Myocarditis and Clinical Feasibility in a Large Cohort of Patients with Acute Cardiac DecompensationFelicitas Escher, Heiko Pietsch, Ganna Aleshcheva, et al.
European Journal of Heart Failure|January 16, 2023
Effect of allogeneic adipose tissue-derived mesenchymal stromal cell treatment in chronic ischaemic heart failure with reduced ejection fraction - the SCIENCE trialAbbas Ali Qayyum, Bas van Klarenbosch, Sabina Frljak, et al.
American Heart Journal|December 19, 2025
Corrigendum to "Long-term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trials" [American Heart Journal (278)2024 Page Number:106-116]Sheldon E Litwin, Jan Komtebedde, Barry A Borlaug, et al.
American Heart Journal|September 5, 2024
Long term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trialsSheldon E Litwin, Jan Komtebedde, Barry A Borlaug, et al.
Circulation Research|February 21, 2015
Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient dataMariann Gyöngyösi, Wojciech Wojakowski, Patricia Lemarchand, et al.
Circulation|December 28, 2018
Impella Support for Acute Myocardial Infarction Complicated by Cardiogenic ShockBenedikt Schrage, Karim Ibrahim, Tobias Loehn, et al.
Circulation|March 31, 2022
Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart FailureBarry A Borlaug, John Blair, Martin W Bergmann, et al.
JACC. Cardiovascular Interventions|May 25, 2024
Left Atrial Appendage Occlusion in Patients With Anticoagulation Failure vs Anticoagulation ContraindicationErrol W Aarnink, Moniek Maarse, Nicolai Fierro, et al.
JAMA Neurology|October 7, 2024
Left Atrial Appendage Occlusion vs Standard of Care After Ischemic Stroke Despite AnticoagulationMoniek Maarse, David J Seiffge, David J Werring, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
ESC Heart Failure|October 13, 2018
Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fractionDavid M Kaye, Mark C Petrie, Scott McKenzie, et al.
Journal of Clinical Medicine|August 23, 2020
Evaluation of Myocardial Gene Expression Profiling for Superior Diagnosis of Idiopathic Giant-Cell Myocarditis and Clinical Feasibility in a Large Cohort of Patients with Acute Cardiac DecompensationFelicitas Escher, Heiko Pietsch, Ganna Aleshcheva, et al.
European Journal of Heart Failure|January 16, 2023
Effect of allogeneic adipose tissue-derived mesenchymal stromal cell treatment in chronic ischaemic heart failure with reduced ejection fraction - the SCIENCE trialAbbas Ali Qayyum, Bas van Klarenbosch, Sabina Frljak, et al.
American Heart Journal|December 19, 2025
Corrigendum to "Long-term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trials" [American Heart Journal (278)2024 Page Number:106-116]Sheldon E Litwin, Jan Komtebedde, Barry A Borlaug, et al.
American Heart Journal|September 5, 2024
Long term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trialsSheldon E Litwin, Jan Komtebedde, Barry A Borlaug, et al.
Circulation Research|February 21, 2015
Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient dataMariann Gyöngyösi, Wojciech Wojakowski, Patricia Lemarchand, et al.
Circulation|December 28, 2018
Impella Support for Acute Myocardial Infarction Complicated by Cardiogenic ShockBenedikt Schrage, Karim Ibrahim, Tobias Loehn, et al.
Circulation|March 31, 2022
Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart FailureBarry A Borlaug, John Blair, Martin W Bergmann, et al.
JACC. Cardiovascular Interventions|May 25, 2024
Left Atrial Appendage Occlusion in Patients With Anticoagulation Failure vs Anticoagulation ContraindicationErrol W Aarnink, Moniek Maarse, Nicolai Fierro, et al.
JAMA Neurology|October 7, 2024
Left Atrial Appendage Occlusion vs Standard of Care After Ischemic Stroke Despite AnticoagulationMoniek Maarse, David J Seiffge, David J Werring, et al.
Pageof 10